# T-knife Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/t-knife-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.t-knife.com
- Total disclosed funding: $188M
- Latest round: Series B (Apr 15, 2021)
- Investors on record: 10

## About

Based in Delaware, US, and founded in 2018 by CEO Thomas Blankenstein and CTO Elisa Kieback, T-Knife GmbH is a biopharmaceutical firm that creates treatments for T cell receptors (TCRs). In April 2021, T-Knife GmbH raised USD 110 million in Series B funding led by Fidelity Investments, with participation from CaaS Capital Management, Casdin Capital, Life Sciences Partners, Qatar Investment Authority, Sixty Degree Capital, Andera Partners, RA Capital, and Versant Ventures also participated in the round. T-Knife GmbH secured USD 110 million in Series B investment sponsored by Fidelity Investments in August 2021.

The company is a T-cell receptor (TCR) firm that is developing a pipeline of novel medicines for patients with solid tumors. T-knife is leveraging its proprietary HuTCR transgenic mouse platform to discover and develop a portfolio of TCR-T programs to treat patients with solid tumors. The company’s lead program, TK-8001, is a novel TCR-T product targeting MAGE-A1-positive cancers. T-knife is also developing a pipeline of potential TCR therapeutics against targets with unmet medical needs, including cancer-testis antigens, viral antigens, and commonly shared neoantigens.

## Funding rounds

- Series B, Apr 15, 2021, $110M — Versant Ventures, Andera Partners, EQT Life Sciences, Qatar Investment Authority, Fidelity Investments, Casdin Capital, RA Capital Management, Sixty Degree Capital, CaaS Capital Management
- Series A, Aug 4, 2020, $78M — Versant Ventures, Andera Partners, Boehringer Ingelheim Venture, RA Capital Management

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series B
- CaaS Capital Management (https://capitalatlas.ai/funds/caas-capital-management) — Series B